SPL 1.60% $1.27 starpharma holdings limited

2015 a Watershed Year for Starpharma, Says Bell Potter

  1. 173 Posts.
    lightbulb Created with Sketch. 3
    DJ 2015 a Watershed Year for Starpharma, Says Bell Potter -- Market Talk
    [5:48 ET] Starpharma's (SPL.AU) recent A$21.5 million capital raising prompts Bell
    Potter to cut its price target by 10% to A$0.99/share, but the broker remains upbeat
    about the stock's prospects. Starpharma's cash balance stands at around A$39.3
    million, which would allow it comfortably to progress its pipeline of advanced drugs, the
    broker says. Interest is building in Starpharma's dendrimer-docetaxel drug in
    development, following positive preliminary data from trials on animals and a phase-one
    trial in humans. Bell Potter, which retains a buy call, says the company is better
    equipped to engage in meaningful licensing discussions with both existing and potential
    partners on its various drug-delivery program. Separately, Bell Potter thinks
    Starpharma's VivaGel Coated Condom will start generating revenue from the second
    half of 2015, rising to US$20 million in FY21 as the product is launched in new markets
    and marketing encourages more people to try it. SPL last traded at A$0.475.
watchlist Created with Sketch. Add SPL (ASX) to my watchlist
(20min delay)
Mkt cap ! $464.6M
Open High Low Value Volume
$1.25 $1.29 $1.23 $396.2K 313.2K

Buyers (Bids)

No. Vol. Price($)
6 7785 $1.27

Sellers (Offers)

Price($) Vol. No.
$1.27 14552 6
View Market Depth
Last update - 15.50pm 26/04/2019 (20 minute delay) ?
0.020 ( 1.20 %)
Open High Low Volume
$1.25 $1.29 $1.24 32512
Last updated 15.59pm 26/04/2019 (live) ?
SPL (ASX) Chart
GET SUPPORT arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.